New antibody shows promise for tough thyroid eye disease
NCT ID NCT06269393
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called IBI311 in 53 people with thyroid eye disease that did not get better with steroids. The drug is a modified antibody that blocks a specific receptor. The main goal was to see if it could reduce eye bulging. The trial was completed and compared IBI311 to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI311 (a modified antibody that blocks IGF-1 receptors)
What this could lead to
If successful, this could offer a new treatment option for people with thyroid eye disease who do not respond well to steroids.
What could go wrong
This is an early exploratory study with only 53 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID ASSOCIATED OPHTHALMOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100034, China